4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

Inclusion Criteria:

* Patient has histologically proven squamous cell carcinoma of the head and neck which is biopsy accessible and is not considered curable by standard measures.
* Patient has a Karnofsky performance status \>/= 70%
* Patient has adequate bone marrow function: \*WBC \>/= 3,000 cells/mm\^3, \*ANC \>/= 1,500 cells/mm\^3, \*platelet count \>/= 100,000 cells/mm\^3, \*Hgb \>/= 9.0 g/dL.
* Patient has adequate liver function: \*total bilirubin level \</= 2.0 mg/dL, \*albumin \>/= 2.5 g/dL.
* Transaminases (SGOT and/or SGPT) may be up to 2.5 x ULN if alkaline phosphatase is \</= ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are \</= ULN.
* Patient has adequate renal function: a serum creatinine \< 2 mg/dl
* Patient has signed a written informed consent.
* Patient has received no more than 2 prior chemotherapeutic regimens for recurrent or metastatic disease. Prior biologic therapy is not included.

Exclusion Criteria:

* Patient has received 3 or more prior chemotherapeutic regimens for recurrent/metastatic disease.
* No biopsy accessible tissue.
* Patient has received radiation therapy within the past 6 months.
* Prior radiation to the biopsy site.
* Patient has signs or symptoms of acute infection requiring systemic therapy.
* Patient exhibits confusion, disorientation, or has a history of major psychiatric illness which may impair patient's understanding of the informed consent.
* Patient has grade 3 or 4 neurotoxicity from previous anticancer treatment or significant neuropathy from any cause.
* Patient requires total parenteral nutrition with lipids.
* Surgery is anticipated to leave patient unable to swallow the SCH66336 or 4-HPR daily.
* Patient has a history of uncontrolled heart disease (including arrhythmia, angina, congestive heart failure, or any heart condition that cannot be controlled with regular ongoing medication)
* Because of the known teratogenic effect of retinoids, pregnant women and women who are currently breast-feeding may not participate in this study. All women of childbearing potential must have a negative pregnancy test within 24 hours prior to enrolling in the study.
* Serious infection or other intercurrent illness requiring immediate therapy.
* Inability to swallow oral medications, or other medical or social factors interfering with compliance.
* Patients may not take high dose synthetic or natural Vitamin A derivatives (\>10,000 IU per day). Patients may not be taking high-dose vitamin A within 30 days of study entry.
* Patients should not take any anti-oxidants such as Vitamin E or Vitamin C
* Patients with pre-existing retinopathy